Contents. Contents (13) 1 Production (23)

Size: px
Start display at page:

Download "Contents. Contents (13) 1 Production (23)"

Transcription

1 1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing (31) 1.B.1.1 Clothing material (34) 1.B.1.2 Design of the clothing (35) 1.B.1.3 Preparation/Cleaning (39) 1.B.1.4 Gowning procedure (40) 1.B.2 Code of Conduct (41) 1.B.2.1 Personal hygiene (41) 1.B.2.2 General requirements (42) 1.B.2.3 Special requirements for clean rooms (42) 1.B.2.4 Policies to be established (43) 1.B.3 Hand disinfection (44) 1.B.4 Health requirements (45) 1.B.5 Training (46) 1.C Production hygiene (47) 1.C.1 Sources of contamination (50) 1.C.1.1 Premises and facilities (50) 1.C.1.2 Starting materials (52) 1.C.1.3 Packaging materials (52) 1.C.1.4 Cleansing agents, disinfectants and aids (53) 1.C.1.5 Equipment and utensils (54) 1.C.1.6 Process gases (55) 1.C.1.7 Ambient air (55) 1.C.1.8 Processes (56) 1.C.2 Cleaning (56) 1.C.2.1 Cleaning procedure for equipment (57) 1.C.2.2 Cleaning procedure for rooms (57) 1.C.3 Disinfection (58) 1.C.3.1 General procedure (58) 1.D Sanitation programme (61) 1.D.1 Organisation of room cleaning (61) 1.D.1.1 Hygienic areas (61) (13)

2 1.D.1.2 General room cleaning (61) 1.D.1.3 Cleansing agents and disinfectants (62) 1.D.1.4 Cleaning process and aids (64) 1.D.2 Documentation (65) 1.E Environmental monitoring (67) 1.E.1 General (67) 1.E.2 Sampling plan (69) 1.E.3 Establishment of limits and frequencies (70) 1.E.3.1 European requirements (70) 1.E.3.2 US requirements (73) 1.E.3.3 ISO standards (74) 1.E.4 Methods (75) 1.E.4.1 Direct contact test (75) 1.E.4.2 Measurement of airborne microbes (75) 1.E.5 Investigation areas (77) 1.E.5.1 Surfaces (77) 1.E.5.2 Air (78) 1.E.5.3 Cleansing agents and disinfectants (80) 1.E.5.4 Personnel (81) 1.E.5.5 Utilities (82) 1.E.6 Evaluation (82) 1.E.6.1 Report (82) 1.E.6.2 Trend analyses (82) 1.E.6.3 Measures when limit is exceeded (83) 1.F GMP in the production process (85) 1.G Weigh-in (89) 1.G.1 Legal requirements (89) 1.G.2 Weigh-in principles (91) 1.G.2.1 Product-specific weigh-in (92) 1.G.2.2 Raw material-specific weigh-in (92) 1.G.2.3 Central/local weigh-in systems (93) 1.G.2.4 Manual weigh-in (93) 1.G.2.5 Automatic weigh-in (94) 1.G.3 Weigh-in procedure (95) 1.G.3.1 Allocation of raw materials (96) 1.G.3.2 Weigh-in (96) 1.G.3.3 Return (98) 1.G.3.4 Allocation for production (98) 1.G.3.5 Cleaning (98) 1.G.4 Documentation (99) 1.H Identification (101) 1.H.1 Handling of labels (101) 1.H.2 Labelling of starting materials (102) (14)

3 1.H.3 Labelling of equipment and containers (103) 1.H.3.1 General (103) 1.H.3.2 Rejection / Quarantine (104) 1.H.3.3 Cleaning status (105) 1.H.4 Labelling of rooms (107) 1.I In-process control (109) 1.I.1 Objectives (110) 1.I.1.1 Quality control (110) 1.I.1.2 Process control (110) 1.I.2 Organisation and responsibilities (111) 1.I.3 Carrying out (112) 1.I.3.1 Scope and kind of tests (112) 1.I.3.2 Location (115) 1.I.3.3 Sampling (115) 1.I.3.4 Testing (116) 1.I.4 Documentation and evaluation of data (116) 1.J Prevention of cross-contamination (119) 1.J.1 Causes of cross-contamination (119) 1.J.1.1 Rooms (120) 1.J.1.2 Equipment (120) 1.J.1.3 Processes (122) 1.J.1.4 Personnel (122) 1.J.2 Measures to prevent cross-contamination (123) 1.J.3 Manufacture of critical products (124) 1.K Deviations (127) 1.K.1 Definition (127) 1.K.2 Procedure (128) 1.K.3 Responsibilities (130) 1.K.4 Measures (130) 1.K.5 Failure investigation report (131) 1.K.6 Evaluation of measures (133) 1.K.7 SOP deviations (example) (135) 1.K.8 Check-list for deviation handling (140) 1.L Reworking (145) 1.L.1 Definitions (145) 1.L.1.1 Rework (145) 1.L.1.2 Reprocessing (145) 1.L.1.3 Recovery (145) 1.L.2 Procedure (146) 1.L.2.1 Reasons for rework / reprocessing (146) 1.L.2.2 Request for rework / reprocessing (146) 1.L.2.3 Risk assessment (146) 1.L.2.4 Responsibilities (147) (15)

4 1.L.2.5 Documentation requirements (147) 1.L.2.6 Regulatory submission requirements (148) 1.L.3 Rework / Reprocessing of rejected products (148) 1.L.4 Rework of returned products (152) 1.L.5 Rework of products that have not been rejected (152) 1.M Warehouse and logistics (155) 1.M.1 Regulatory requirements (155) 1.M.2 Stock management system (156) 1.M.3 Responsibilities (160) 1.M.4 Personnel (160) 1.M.5 Storage areas (161) 1.M.5.1 Size (161) 1.M.5.2 Illumination (161) 1.M.5.3 Incoming goods and dispatch (161) 1.M.5.4 Sampling (162) 1.M.5.5 Quarantine (163) 1.M.5.6 Special storage areas (166) 1.M.6 Storage conditions (167) 1.M.6.1 Temperature and humidity (167) 1.M.6.2 Monitoring (167) 1.M.6.3 Deviation handling (170) 1.M.7 Sanitation and pest control (170) 1.M.8 Material Flow (172) 1.M.8.1 Stock rotation (172) 1.M.8.2 Reconciliation (173) 1.M.8.3 Storage systems (173) 1.M.9 Process Flow (176) 1.M.9.1 Receipt (176) 1.M.9.2 Identification (179) 1.M.9.3 Dispatch and transport (181) 2 Packaging (183) 2.A Packaging material (185) 2.A.1 Responsibilities (186) 2.A.2 (186) 2.A.3 Materials (186) 2.A.4 Protection against counterfeit medicinal products (190) 2.A.5 Packaging material testing (191) 2.A.5.1 Control tests carried out at the supplier (191) 2.A.5.2 Examples (192) 2.A.5.3 Defect evaluation lists (193) 2.A.5.4 Storage (195) 2.A.5.5 Labelling (196) (16)

5 2.B Packaging process (199) 2.B.1 Allocation of packaging material (200) 2.B.2 Line clearance (201) 2.B.3 Labelling (204) 2.B.4 Control functions (204) 2.B.5 Release for production (206) 2.B.6 In-process controls (213) 2.B.6.1 Organisation (213) 2.B.6.2 Function inspections (216) 2.B.6.3 Checking (partially) packed goods (218) 2.B.7 Cleaning primary containers (219) 2.B.8 Labelling (219) 2.B.9 Variable data (220) 2.B.10 Imprints (221) 2.B.11 Reconciliation (222) 2.B.12 Safety features (224) 2.B.13 Completion of a packaging process (224) 2.C Qualification of a packaging line (225) 2.C.1 Master qualification plan (226) 2.C.2 Design qualification (DQ) (232) 2.C.2.1 Design qualification protocol (232) 2.C.2.2 Design qualification report (234) 2.C.3 Installation qualification (IQ) (248) 2.C.3.1 Installation qualification protocol (248) 2.C.3.2 Installation qualification report (253) 2.C.4 Operational qualification (OQ) (258) 2.C.4.1 Operational qualification protocol (258) 2.C.4.2 Operational qualification report (263) 2.C.5 Performance qualification (PQ) (270) 2.C.5.1 Performance qualification protocol (270) 2.C.5.2 Performance qualification report (273) 3 Laboratory and Analytical Controls (277) 3.A Sampling (281) 3.A.1 Requirements (282) 3.A.1.1 Personnel (282) 3.A.1.2 Equipment (282) 3.A.1.3 Containers (283) 3.A.1.4 Premises (283) 3.A.2 Sampling plan (instructions) (283) 3.A.3 Notes for the sampling process (288) 3.A.3.1 Containers and identification labeling (288) 3.A.3.2 Sampling report (288) 3.A.3.3 Reference samples (289) (17)

6 3.B Reagents (291) 3.B.1 Labeling (292) 3.B.2 Usage and stability (292) 3.B.3 Documentation (294) 3.C Standards and reference substances (297) 3.C.1 Definition of different standards and their areas of use (297) 3.C.2 Handling, storage and stability (301) 3.D Qualifying laboratory instruments (305) 3.D.1 Qualification protocols and reports (305) 3.D.1.1 Design qualification (DQ) (306) 3.D.1.2 Installation qualification (IQ) (308) 3.D.1.3 Operational qualification (OQ) (308) 3.D.1.4 Performance qualification (PQ) (308) 3.D.2 System suitability test (SST) (309) 3.E Calibration in the lab (311) 3.E.1 Definitions (311) 3.E.1.1 Persons (311) 3.E.1.2 Instruments (311) 3.E.1.3 Working (312) 3.E.1.4 Laboratory Equipment Inventory List (313) 3.E.2 Calibration instructions and record (314) 3.E.2.1 Test intervals, test points, test instructions (314) 3.E.3 Examples (315) 3.E.3.1 Balance (315) 3.E.3.2 Volume measuring instruments (317) 3.E.3.3 Photometer (319) 3.E.3.4 HPLC system (321) 3.E.4 Decision (330) 3.E.4.1 Requirements, tolerances, specifications (330) 3.E.4.2 Equipment release (330) 3.E.4.3 Out of calibration (330) 3.F Validation of analytical methods (331) 3.F.1 Principles (331) 3.F.2 Definitions of the parameters (333) 3.F.2.1 Precision (333) 3.F.2.2 Accuracy (333) 3.F.2.3 LOD = Limit of Detection (334) 3.F.2.4 LOQ = Limit of Quantitation (334) 3.F.2.5 Selectivity (335) 3.F.2.6 Linearity, Range (335) 3.F.2.7 Robustness (335) 3.F.3 Documentation (336) 3.F.4 Revalidation (336) (18)

7 3.G Stability testing (339) 3.G.1 ICH guidelines for stability tests (340) 3.G.2 Storage and storage conditions (342) 3.G.2.1 Standard storage conditions (342) 3.G.2.2 Packaging (345) 3.G.2.3 Sample quantities (346) 3.G.2.4 Stress test (346) 3.G.2.5 Freeze test (347) 3.G.2.6 Temperature cycling test (348) 3.G.2.7 Special storage conditions for drug products (348) 3.G.2.8 Labeling (350) 3.G.3 Analyses (351) 3.G.3.1 Test parameters (352) 3.G.3.2 Reference samples (353) 3.G.3.3 Consumption test (353) 3.G.3.4 Compatibility test for injection solutions for infusions (353) 3.G.3.5 Analysis of compatibility of rubber stoppers and plastic components (353) 3.G.3.6 Photostability (ICH Q1B) (354) 3.G.3.7 Microbiological analyses (356) 3.G.3.8 Analysis of standing times (357) 3.G.3.9 Analysis of transport conditions (357) 3.G.4 Reduction of the study design (358) 3.G.4.1 Bracketing (359) 3.G.4.2 Matrixing (359) 3.G.5 Stability testing in the marketing phase (362) 3.G.5.1 Follow-up stability testing (FuST) (362) 3.G.5.2 Stability commitment (SC) (363) 3.G.6 Defining the retest period for an active pharmaceutical ingredient and the shelf life for a drug product through evaluation of stability data (ICH Q1E) (375) 3.G.6.1 Data evaluation for the retest period for APIs and shelf life for drug products that are intended for storage at room temperature (375) 3.G.6.2 Data evaluation for retest period for APIs and shelf life for drug products intended for storage in refrigerator (2 8 C) (377) 3.G.6.3 Data evaluation for retest period for APIs and shelf life 3.G.7 for drug products for intended storage in a freezer ( 20 C) (378) Decision tree for data evaluation for retest period or for APIs or drug products (excluding frozen products) (378) 3.G.8 Procedure for statistical analysis (378) 3.G.9 Examples of the statistical evaluation of stability data (380) 3.G.9.1 Data analysis for a single batch (380) 3.G.9.2 Data analysis of one attribute in each batch for several batches of the same product (known as One-Factor, Full-Design Studies) (381) (19)

8 3.G.9.3 Data analysis of all attributes for several batches (Multi-Factor, Full-Design Studies) (382) 3.H Out-of-specification results (383) 3.H.1 Significance (383) 3.H.1.1 The BARR Laboratories case (383) 3.H.1.2 The consequences (385) 3.H.2 Definitions (386) 3.H.3 FDA OOS Guidance (386) 3.H.4 Example for handling of an OOS result (394) 3.H.5 Trend tracking (395) 3.I Raw data documentation (403) 3.I.1 Principles (403) 3.I.2 Single sheet documentation system (405) 3.I.2.1 Cover sheet (405) 3.I.2.2 Data sheet (405) 3.I.2.3 Index sheet (409) 3.J Batch release (411) 3.J.1 Certification by a Qualified Person and release in accordance with EC GMP Guidelines (414) 3.J.1.1 Regulations contained in Directive 2001/83/EC (414) 3.J.1.2 Objectives of appendix 16 (415) 3.J.1.3 Cases of application (416) 3.J.2 Responsibility for issuing the release (418) 3.J.3 Publication of release (419) 3.J.4 Release procedures in practice (420) 3.K Microbiological testing (423) 3.K.1 Total microbial count (424) 3.K.1.1 Determination of the total microbial count (432) 3.K.1.2 Product testing (438) 3.K.1.3 Culture media and culture media checks (440) 3.K.1.4 Incubation (443) 3.K.1.5 Evaluation (443) 3.K.1.6 Validation of the method (445) 3.K.2 Specified microorganisms (446) 3.K.2.1 Detection of specified microorganisms (452) 3.K.2.2 Detection method for the specified microorganisms (454) 3.K.2.3 Evaluation (463) 3.K.2.4 Culture media and culture media tests (464) 3.K.2.5 Suitability test of the method (validation of the methods) (469) 3.K.3 Testing frequencies (470) 3.K.3.1 Preparations (470) 3.K.3.2 Raw materials (471) 3.K.4 Miscellaneous tests (474) (20)

9 3.K.4.1 Monitoring of the hygiene status (474) 3.K.4.2 Aseptic working conditions (477) 4 Documentation (479) 4.A Official requirements (481) 4.A.1 GMP-requirements managed and reviewed according to German pharma business regulations (481) 4.A.2 Requirements of the EU GMP Guideline (484) 4.A.3 Requirements of the US GMP Regulations (488) 4.A.4 Formal requirements (493) 4.A.5 Management and revision documentation (497) 4.B GMP-conforming documentation (501) 4.B.1 Handwritten entries (501) 4.B.2 Archiving (502) 4.B.3 Master-SOP GMP-conforming documentation (503) 4.C Batch documentation (509) 4.C.1 Manufacturing instructions/record (511) 4.C.1.1 Manufacturing instructions (511) 4.C.1.2 Batch processing record (512) 4.C.1.3 Master of manufacturing instructions/batch processing record (514) 4.C.2 Packaging instruction and batch packaging record (534) 4.C.2.1 Packaging instruction (534) 4.C.2.2 Batch packaging record (535) 4.C.3 Electronic batch recording (536) 4.C.3.1 Strategic objectives of an Electronic Batch Recording System (EBRS) (537) 4.C.3.2 GMP aspects (537) 4.C.4 Testing procedures and test protocol (539) 4.C.4.1 Testing procedures (539) 4.C.4.2 Test protocol (541) 4.C.5 Batch record review (544) 4.C.5.1 Regulatory requirements (544) 4.C.5.2 Benefits of an independent batch record review (544) 4.C.5.3 Responsibility and competencies (545) 4.C.5.4 Scope of a batch record review (545) 4.C.5.5 Deviations, changes relevant to marketing authorization, recording errors (546) 4.D Standard operating procedures (SOPs) (549) 4.D.1 Compilation (550) 4.D.1.1 Design and format (552) 4.D.1.2 Identification (554) 4.D.2 Approval and implementation (555) 4.D.3 Training (555) 4.D.4 Usage (556) (21)

10 4.D.5 Review (557) 4.D.6 Changes (557) 4.D.7 Withdrawing an operating procedure (558) 4.D.8 Administration (558) 4.D.8.1 Status identification (558) 4.D.8.2 Distribution (558) 4.D.8.3 Integration (559) 4.D.8.4 Use of computerized systems (559) 4.D.9 Archiving (560) 4.D.10 Example of an SOP Compilation and administration of operating procedures (561) 4.E Site master file (577) 4.E.1 Introduction (577) 4.E.2 Design (577) 4.E.2.1 General information (578) 4.E.2.2 Personnel (579) 4.E.2.3 Premises and equipment (580) 4.E.2.4 Documentation (583) 4.E.2.5 Production (585) 4.E.2.6 Quality control (586) 4.E.2.7 Contract manufacturing and analysis (586) 4.E.2.8 Distribution, complaints and product recall (587) 4.E.2.9 Self-inspection (588) 4.E.2.10 Appendix (589) 4.F Annual product review / Product quality review (591) 4.F.1 Documents required for an annual product review (594) 4.F.2 Annual product review report (596) 4.F.3 Collaboration with a contract manufacturer (598) 4.F.4 Example: annual product review (599) 4.F.5 Master-SOP for the annual product review (604) Index (609) (22)

GMP MANUAL Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel

GMP MANUAL Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel GMP MANUAL GMP MANUAL 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C (1) 1.C.2 Documentation

More information

GMP MANUAL Contents. 1 Pharmaceutical Quality System (PQS)

GMP MANUAL Contents. 1 Pharmaceutical Quality System (PQS) GMP MANUAL GMP MANUAL 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C.2 Documentation 1.D Main

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.

More information

GMP On Site Series. GMP Essentials

GMP On Site Series. GMP Essentials GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history

More information

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address: NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a

More information

LEGAL REQUIREMENTS FOR STABILITY

LEGAL REQUIREMENTS FOR STABILITY BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex

More information

18.H Questionnaire for preparing GMP-inspections

18.H Questionnaire for preparing GMP-inspections Questionnaire for preparing -inspections Questionnaire for preparing -inspections Here you will find answers to the following questions: What questions are typically asked during inspections based on current

More information

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

USP Chapter 823 USP 32 (old) vs. USP 35 (new) USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has

More information

WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND

WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Mylan Nashik ( Sinnar in CRM) AND SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer

More information

Library Guide: Active Pharmaceutical

Library Guide: Active Pharmaceutical Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the

More information

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets

Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments

More information

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (16) 86 R2 MANAGEMENT OF ENVIRONMENTAL CONDITIONS Full document title and reference Document type Management of Environmental

More information

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products

UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September

More information

HACCP audit checklist

HACCP audit checklist Requirement HACCP audit checklist Prerequisite Program Management Commitment 1. Senior management ensures that the responsibilities and authorities are defined and communicated within the company Internal

More information

Annex 4. Guidance on good manufacturing practices: inspection report. Background

Annex 4. Guidance on good manufacturing practices: inspection report. Background Annex 4 Guidance on good manufacturing practices: inspection report Background The need for revision of the Guidance on good manufacturing practices: inspection report (World Health Organization (WHO)

More information

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec 2004 Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland cca@iol.ie 1 FDA Context 1) FDA 5-Part Strategic Plan Protect &

More information

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

More information

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1 General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)

More information

Annex 14 WHO guidelines for drafting a site master file 136

Annex 14 WHO guidelines for drafting a site master file 136 World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix

More information

On-Site GMP Training GMP COMPLIANCE TECHNICAL

On-Site GMP Training GMP COMPLIANCE TECHNICAL PharmaNet On-Site GMP Training GMP COMPLIANCE TECHNICAL 284 E Lake Mead Pkwy Suite C-278 Henderson, NV 89015 Phone: 702-558-0094 Fax: 702-558-0079 www.gmpseminars.com Key to Level of Program Level A: Program

More information

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 009-11 (Part I) 1 March 2014 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I PIC/S March 2014 Reproduction

More information

HISTORY AND MILESTONES

HISTORY AND MILESTONES HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing

More information

Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators

Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Regional GMP Strengthening Workshop for Indian Pharmaceutical Manufacturers and State Regulators Focused on GMP in production of Active Pharmaceutical Ingredients and Oral Solid Dosage Forms Organized

More information

Good Manufacturing Practices Guidance Document

Good Manufacturing Practices Guidance Document Good Manufacturing Practices Guidance Document Natural Health Products Directorate June 11, 2014 Version 3.0 Table of Contents Foreword... 3 1.0 General overview... 4 1.1 Purpose of the good manufacturing

More information

COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION

COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,

More information

Risk classification guide for drug good manufacturing practices observations GUI-0023

Risk classification guide for drug good manufacturing practices observations GUI-0023 Risk classification guide for drug good manufacturing practices observations GUI-0023 January 18, 2017 Risk classification guide for drug good manufacturing practices observations (GUI-0023) Author: Health

More information

Quality Assessment & GMP Similarities & Differences

Quality Assessment & GMP Similarities & Differences Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences

More information

Table of Contents. Legal Notices... 61

Table of Contents. Legal Notices... 61 Notice This manual provides information to excipient manufacturers who intend to participate in the United States Pharmacopeia Ingredient Verification Program for Excipients (USP IVP-E or Program). The

More information

Conducting Supplier Audits: Ensure Validation Compliance

Conducting Supplier Audits: Ensure Validation Compliance Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why

More information

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU

White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between

More information

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products

WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles

More information

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART II

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART II PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 009-8 (Part II) 15 January 2009 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART II Developed by the

More information

Aseptic Process Validation

Aseptic Process Validation Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic

More information

GMP Requirements Based On WHO Guidelines for Ayush Premium Mark

GMP Requirements Based On WHO Guidelines for Ayush Premium Mark SECTION III VOLUNTARY CERTIFICATION SCHEME FOR AYUSH PRODUCTS Certification Criteria Annex A GMP Requirements Based On WHO Guidelines for Ayush Premium Mark 1. Introduction The increasing use of herbal

More information

Good Manufacturing Practices (GMPs) for Infant Formula

Good Manufacturing Practices (GMPs) for Infant Formula Good Manufacturing Practices (GMPs) for Infant Formula Nutrition Evaluation Division Bureau of Nutritional Sciences Health Products and Food Branch Health Canada 2006 Good Manufacturing Practices (GMPs)

More information

GOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS. (Made under section 122(1)(o))

GOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS. (Made under section 122(1)(o)) GOVERNMENT NOTICE NO. published on THE TANZANIA FOOD, DRUGS AND COSMETICS ACT (CAP 219) REGULATIONS (Made under section 122(1)(o)) THE TANZANIA FOOD, DRUGS AND COSMETICS (GOOD MANUFACTURING PRACTICE ENFORCEMENT)

More information

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt

SESSION 14. Documentation Requirements and Management for Validation. 30 March Frits Vogt Validation Services SESSION 14 Documentation Requirements and Management for Validation 30 March 2017 Frits Vogt fritsvogt@valserv.nl Content Documentation Requirements and Management for Validation I.

More information

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS

EUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible

More information

PROCESS VALIDATION: AN ESSENTIAL PROCESS IN PHARMACEUTICAL INDUSTRY

PROCESS VALIDATION: AN ESSENTIAL PROCESS IN PHARMACEUTICAL INDUSTRY WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Vijayasree et al. SJIF Impact Factor 6.647 Volume 6, Issue 3, 367-874 Review Article ISSN 2278 4357 PROCESS VALIDATION: AN ESSENTIAL PROCESS IN PHARMACEUTICAL

More information

Self-Evaluation/Audit Checklist for Food Supplement Manufacturers

Self-Evaluation/Audit Checklist for Food Supplement Manufacturers Self-Evaluation/Audit Checklist for Food Supplement Manufacturers This checklist has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations

More information

APIC GUIDE FOR AUDITING REGISTERED STARTING MATERIAL MANUFACTURERS Version February, 2018

APIC GUIDE FOR AUDITING REGISTERED STARTING MATERIAL MANUFACTURERS Version February, 2018 APIC GUIDE FOR AUDITING REGISTERED STARTING MATERIAL MANUFACTURERS Version February, 2018 1. PREAMBLE This original version of this guidance document has been compiled by a subdivision of the APIC 3 rd

More information

Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines

Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines Longe Sunday Anthony Head- Quality Assurance May & Baker Nigeria Plc. Pharmacentre, Ota, Nigeria eaglesconsult@gmail.com; Slonge@may-

More information

PERFORMANCE QUALIFICATION PROTOCOL HVAC SYSTEM

PERFORMANCE QUALIFICATION PROTOCOL HVAC SYSTEM Page 1 of 24 PERFORMANCE QUALIFICATION PROTOCOL FOR HVAC SYSTEM Signing of this Performance Qualification Protocol indicates agreement with the Validation Master Plan approach of the equipment. Further

More information

American Association for Laboratory Accreditation

American Association for Laboratory Accreditation Page 1 of 34 This checklist is intended for use in association with A2LA assessments, and is not to be publicly distributed. Use of this document is restricted to A2LA employees, contractors, and applicant

More information

Questionnaire Layout:

Questionnaire Layout: Raw Material Supplier Questionnaire Introduction: This questionnaire has been developed by the EHPM quality working group. It combines work carried out by EHPM various national associations in developing

More information

Standard Answers to FAQs from Customer Questionnaires

Standard Answers to FAQs from Customer Questionnaires Standard Answers to FAQs from Customer Questionnaires 1. Organisation 1.1 Details about the company Company name Hänseler AG Street Industriestrasse 35 Postcode, town 9100 Herisau Country Switzerland Homepage

More information

GMPs: Distribution Centers

GMPs: Distribution Centers SkillsPlus International Inc. The On-Site Series GMPs: Distribution Centers Learn to apply the GMP regulations as they relate to distribution center operations! FDA Past, Present, and Future and opener

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION 1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS

More information

A.1 Contents file 4 to 5 A.1 (1)

A.1 Contents file 4 to 5 A.1 (1) Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY  ISSN Review Article INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C

More information

EU and FDA GMP Regulations: Overview and Comparison

EU and FDA GMP Regulations: Overview and Comparison THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational

More information

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality

More information

GMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)

GMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) GMP Requirements Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) 2016. ALL RIGHTS RESERVED. Outline GMP Procedures and standards

More information

Your partner in the pharmaceutical industry

Your partner in the pharmaceutical industry English Micronisation- and milling service Micronised by GfM Your API Particle size (µm) Your partner in the pharmaceutical industry The... always that little bit finer. We are a family business in the

More information

COMMERCIAL PRODUCT STABILITY

COMMERCIAL PRODUCT STABILITY COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality

More information

API Stability Protocols and. Chris Byrne Tasmanian Alkaloids

API Stability Protocols and. Chris Byrne Tasmanian Alkaloids API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood

More information

Lifecycle Product Quality Risk Management

Lifecycle Product Quality Risk Management Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,

More information

Annex 6. Good trade and distribution practices for pharmaceutical starting materials

Annex 6. Good trade and distribution practices for pharmaceutical starting materials Annex 6 Good trade and distribution practices for pharmaceutical starting materials Introduction 212 1. Quality management 213 2. Organization and personnel 214 3. Premises 215 4. Procurement, warehousing

More information

TANZANIA FOOD AND DRUGS AUTHORITY

TANZANIA FOOD AND DRUGS AUTHORITY TANZANIA FOOD AND DRUGS AUTHORITY Doc.No.:TFDA/DMC/MCIE/G/013 Rev. 0 GOOD MANUFACTURING PRACTICE GUIDELINES FOR VETERINARY MEDICINAL PRODUCTS (Made under section 51 of the Tanzania Food, Drugs and Cosmetics

More information

The IFSQN FSSC Implementation Package

The IFSQN FSSC Implementation Package This is our premiere package for Food Manufacturers looking to achieve certification to FSSC 22000 for Food Safety Management Systems. Food Safety System Certification (FSSC) 22000 is a Global Food Safety

More information

MEASURE FOR MEASURE: QUALITY METRICS

MEASURE FOR MEASURE: QUALITY METRICS MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust

More information

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. At Your ServIce Microbiology Services The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Microbiology Services Optimize your QC lab workflow and ensure regulatory compliance

More information

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls

More information

SFHPHARM18 - SQA Unit Code FA2L 04 Prepare aseptic products

SFHPHARM18 - SQA Unit Code FA2L 04 Prepare aseptic products Overview This standard covers the preparation of aseptic products including preparing the environment and self. It covers aseptic preparation for both dispensing and manufacturing. Your practice will be

More information

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Guidelines for Process Validation of Pharmaceutical Dosage Forms Guidelines for Process Validation of Pharmaceutical Dosage Forms Version 2.1 Date issued 21/02/2010 Date of implementation 21/05/2010 31 August 2010 Page 1 of 20 Guidelines for Process Validation of Pharmaceutical

More information

Annex 4. Assessment tool based on the model quality assurance system for procurement agencies: aide memoire for inspection

Annex 4. Assessment tool based on the model quality assurance system for procurement agencies: aide memoire for inspection Annex 4 Assessment tool based on the model quality assurance system for procurement agencies: aide memoire for inspection 1. Introduction 294 2. Purpose 294 3. Scope 294 4. Assessment tool 295 293 WHO

More information

THE BASIC PRINCIPLES OF HACCP

THE BASIC PRINCIPLES OF HACCP THE BASIC PRINCIPLES OF HACCP The Meaning of HACCP History of the HACCP System Traditional Inspection HACCP System The Seven Principles of HACCP ١ Meaning of HACCP : Hazard Analysis and Critical Control

More information

GUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART 1

GUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART 1 GUIDELINES ON GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART 1 National Drug Authority Plot 46-48, Lumumba Avenue, P. O. Box 23096, Kampala, Uganda. Tel: +256-0414 - 255665/347391/2 Fax: +256-0414

More information

Qualified Persons in the Pharmaceutical Industry Study Guide

Qualified Persons in the Pharmaceutical Industry Study Guide Qualified Persons in the Pharmaceutical Industry Study Guide Guide to the knowledge and practical experience required by Qualified Persons relating to pharmaceutical manufacturing in the UK February 2013

More information

Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES

Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES William Garvey and Associates LLC 2016 Introduction About your instructor William (Bill) Garvey Important regulations and events Good Manufacturing

More information

NAFDAC. paths2 GOOD PRACTICES FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES

NAFDAC. paths2 GOOD PRACTICES FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES NAFDAC GOOD PRACTICES FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES 2016 paths2 Partnership for Transforming Health System II...improving pathway to health UKaid from the British people NAFDAC NATIONAL

More information

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document

Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions

More information

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer

Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)

More information

CALIBRATION AND QUALIFICATION OF EQUIPMENTS IN THE PHARMACEUTICAL INDUSTRY: EMPHASIS ON RADIOPHARMACEUTICALS PRODUCTION

CALIBRATION AND QUALIFICATION OF EQUIPMENTS IN THE PHARMACEUTICAL INDUSTRY: EMPHASIS ON RADIOPHARMACEUTICALS PRODUCTION 2011 International Nuclear Atlantic Conference - INAC 2011 Belo Horizonte, MG, Brazil, October 24-28, 2011 ASSOCIAÇÃO BRASILEIRA DE ENERGIA NUCLEAR - ABEN ISBN: 978-85-99141-04-5 CALIBRATION AND QUALIFICATION

More information

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)

CUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions) 21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software

More information

Microbiological Consideration for Non-Sterile Pharmaceutical

Microbiological Consideration for Non-Sterile Pharmaceutical May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control

More information

GOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL STARTING MATERIALS. REVISION

GOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL STARTING MATERIALS. REVISION July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 GOOD TRADE AND DISTRIBUTION PRACTICES FOR PHARMACEUTICAL STARTING MATERIALS.

More information

Journal home page: RESEARCH ARTICLE

Journal home page:  RESEARCH ARTICLE Journal home page: http://www.journalijiar.com INTERNATIONAL JOURNAL OF INNOVATIVE AND APPLIED RESEARCH RESEARCH ARTICLE QUALITY AUDIT AND GMP INSPECTION OF PHARMACEUTICAL INDUSTRY WITH REFERENCE TO USFDA;

More information

Comparison of Guidelines of Indian GMP with WHO GMP

Comparison of Guidelines of Indian GMP with WHO GMP Comparison of Guidelines of Indian GMP with WHO GMP By Dr. Uma Vasireddy, M.Pharm,Ph.D.., Professor and Principal, KIPS,Wgl, INDIA 1 Outline of Presentation Introductory Elements Section wise Comparison

More information

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT PA/PH/OMCL (13) 113 2R Evaluation and Reporting of Results Core document Full document title and reference Evaluation and Reporting of Results

More information

Environmental Monitoring of Aseptic Processing Areas - 1

Environmental Monitoring of Aseptic Processing Areas - 1 Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Training Course Agenda Overview of Environmental Monitoring

More information

ISO 22000:2005 Standard INTERNATIONAL STANDARDS REGISTRATIONS

ISO 22000:2005 Standard INTERNATIONAL STANDARDS REGISTRATIONS ISO 22000:2005 Standard Food Safety Management System INTERNATIONAL STANDARDS REGISTRATIONS 3.1 FOOD SAFETY concept that food will not cause harm to the consumer when it is prepared and/or eaten according

More information

The Cleaning Validation Process

The Cleaning Validation Process The Cleaning Validation Process The Scope of Cleaning Validation The Cleaning Validation Sequence Prerequisites Cleaning Validation Strategy, Plan, and Policy Sampling Recovery Studies Analytical Method

More information

Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES

Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES DB Schenker Healthcare Conference Europe April 17-18 th 2012 J. BERLO Industrial Pharmacist/Clin. Biol.

More information

For analytical laboratories. A primer Good laboratory practice and current good manufacturing practice

For analytical laboratories. A primer Good laboratory practice and current good manufacturing practice For analytical laboratories A primer Good laboratory practice and current good manufacturing practice For analytical laboratories A primer Good laboratory practice and current good manufacturing practice

More information

Correspondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements

Correspondence Between ISO 13485:2016 and 21 CFR Part 820 QMS Requirements Correspondence Between and 21 CFR Part 820 QMS Requirements 10411 Corporate Drive, Suite 102, Pleasant Prairie, WI 53158 262.842.1250 262.842.1240 info@rcainc.com rcainc.com 2 4 Quality Management System

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer Part 1: General information Name of Manufacturer / Iksan Plant Unit number Production Block Physical address Contact person and email

More information

Process Validation Guidelines. Report highlights 23 rd February 2018

Process Validation Guidelines. Report highlights 23 rd February 2018 Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability

More information

The validation of biological Active Pharmaceutical

The validation of biological Active Pharmaceutical This article presents a procedure for the validation of biological API manufacturing processes. It details each step of the procedure for biological processes applications, and covers the regulatory requirements

More information

Process validation in medical devices

Process validation in medical devices Process validation in medical devices Fulfil requirements with expert regulatory guidance 1TÜV SÜD Contents INTRODUCTION 4 VALIDATION PLANNING 5 INSTALLATION QUALIFICATION 7 OPERATIONAL QUALIFICATION 9

More information

INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW

INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW International Journal of Pharmacy Review & Research www.ijprr.com INDUSTRIAL PROCESS VALIDATION OF TABLET DOSAGE FORM: A REVIEW Vishal Sharma* and Nimrata Seth 1 Department of Pharmaceutics, Rayat Institute

More information

Regulatory Expectations, Standards & Guidelines

Regulatory Expectations, Standards & Guidelines Regulatory Expectations, Standards & Guidelines Regulatory Requirements Pharmacopeias Good Automated Manufacturing Practice (GAMP) 21 CFR Part 11 and Annex 11 Consequences of Non-Compliance 22 Regulatory

More information

Heating, ventilation, and air system encompasses heating, ventilation, and air conditioning, which is integral component of

Heating, ventilation, and air system encompasses heating, ventilation, and air conditioning, which is integral component of REVIEW ARTICLE Demand of pharmaceutical facility functionality: Validation and qualification of HVAC system Anamika Singh, Sapna Malviya, Anil Kharia Department of Quality Assurance of Modern Institute

More information

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness

Validation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp

More information

Annex Draft Annex

Annex Draft Annex Anmerkung 1: Dieses Vergleichsdokument wurde nach bestem Wissen und Gewissen erstellt und ist rechtlich nicht bindend. Es gelten die von der EMA veröffentlichten Dokumente in der jeweiligen Form. Anmerkung

More information

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702

Quality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 11 Status : APPROVED Effective: 09/07/2017 Page 2 of 32 Quality Manual Table of Contents

More information

TECTURA LIFE SCIENCES HIGHLIGHTS

TECTURA LIFE SCIENCES HIGHLIGHTS HIGHLIGHTS BATCH AND SERIAL NUMBER MANAGEMENT QUALITY CONTROL VENDOR RATING ELECTRONIC SIGNATURE AND AUDIT TRAIL R&D MODULE MANAGEMENT OF ACTIVE INGREDIENTS SEQUENCE PLANNING MOBILE SCANNER INTEGRATION

More information

Review Validation of aseptic processes for pharmaceuticals

Review Validation of aseptic processes for pharmaceuticals OPEM www.opem.org Oriental Pharmacy and Experimental Medicine 2010 10(4), 231-238 DOI 10.3742/OPEM.2010.10.4.231 Review Validation of aseptic processes for pharmaceuticals Lincy Joseph*, Mathew George

More information